Organizations
- Outer Biosciences
TechCrunch reports that Outer Biosciences keeps donated human skin viable for up to a month and feeds experimental results back into a predictive model. The company says it has six active leads and has raised about $23 million; those are company claims reported by TechCrunch, not independently validated development results.
What happened
- TechCrunch profiled Outer Biosciences' effort to keep donated human skin viable long enough to run repeated drug experiments.
- Outer says each experiment becomes training data for a model that proposes what to test next, creating a prediction-and-experiment loop.
Why it matters
Human tissue could provide more relevant feedback than simplified cell systems, but the value of the approach will depend on whether its predictions translate into better drug-development decisions.
Key details
- Platform
- Living donated human skin paired with iterative computational prediction
- Company-reported pipeline
- Six active leads
- Funding reported by TechCrunch
- About $23 million
What to watch
- Prospective evidence that the model-and-tissue loop predicts outcomes better than existing preclinical systems.
Event chronology
How the story developed
TechCrunch profile published
TechCrunch published its report on Outer Biosciences' living-skin research platform.
Evidence ledger
Sources behind this brief
- 01
- 02